Nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) are important causes of chronic liver disease in the United States. The NASH Clinical Research Network (NASH CRN) was established in 2002 to conduct research related to its clinical features, risk factors, pathogenesis, natural history and treatment in children and adults. The initial funding period of the NASH CRN has been very productive in establishing and conducting network-wide protocols and numerous ancillary and pilot studies. Encouraged by its success, the NIDDK has issued RFA-DK-08-505 whose objective is to continue the NASH CRN for additional five years, The objectives of the NASH CRN during the next funding period are (a) to successfully complete the 3 network-wide studies initiated during the initial funding period. These include the observational longitudinal study of NAFLD in adults and children (NAFLD Database study, n=l,215), a randomized double blind controlled therapeutic study in adult non diabetic patients with NASH (PIVENS, n=247), and a randomized double blind controlled therapeutic study in children with NASH (TONIC, n=173). The NAFLD Database study will be amended to meet additional goals during the next funding period. These modifications may include extending the length of follow-up of those enrolled, consideration of a follow-up liver biopsy in a subset of patients without cirrhosis for better assessment of histological natural history and enrolling carefully chosen controls without NAFLD (b) to successfully complete the ancillary and pilot studies that have been begun during the initial funding period, (c) to conduct additional therapeutic studies in adults and children with NASH since currently available options to treat NASH are limited. Subsets of patients requiring immediate attention include (but not limited) to those with diabetes because of the higher prevalence and greater severity of disease (d) to initiate and complete additional ancillary studies based on extensive clinical material and biosamples collected thus far. In the present funding period, we propose to complete the specific aims stated above and additionally conduct 2 clinical trials using S adenosyl L-methionine and pentoxifylline, based on sound pathophysiological rationale developed during the initial funding period. Public Health Relevance: (provided by the applicant) NAFLD is the commonest liver disease in North America affecting both children and a third of adults. NASH is a severe form of NAFLD and a significant clinical component of the metabolic syndrome. At least 15% of patients with NASH will progress to develop cirrhosis in an estimated 6 milion Americans. The societal and economic costs of this disease burden provide a compelling public health rationale for the proposed studies.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Research Project--Cooperative Agreements (U01)
Project #
3U01DK061732-08S1
Application #
8012557
Study Section
Special Emphasis Panel (ZDK1-GRB-7 (M1))
Program Officer
Robuck, Patricia R
Project Start
2010-02-01
Project End
2011-01-31
Budget Start
2010-02-01
Budget End
2011-01-31
Support Year
8
Fiscal Year
2010
Total Cost
$149,966
Indirect Cost
Name
Cleveland Clinic Lerner
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
135781701
City
Cleveland
State
OH
Country
United States
Zip Code
44195
Hameed, B; Terrault, N A; Gill, R M et al. (2018) Clinical and metabolic effects associated with weight changes and obeticholic acid in non-alcoholic steatohepatitis. Aliment Pharmacol Ther 47:645-656
Africa, Jonathan A; Behling, Cynthia A; Brunt, Elizabeth M et al. (2018) In Children With Nonalcoholic Fatty Liver Disease, Zone 1 Steatosis Is Associated With Advanced Fibrosis. Clin Gastroenterol Hepatol 16:438-446.e1
Ajmera, Veeral; Belt, Patricia; Wilson, Laura A et al. (2018) Among Patients With Nonalcoholic Fatty Liver Disease, Modest Alcohol Use Is Associated With Less Improvement in Histologic Steatosis and Steatohepatitis. Clin Gastroenterol Hepatol 16:1511-1520.e5
Dasarathy, Srinivasan; Hatzoglou, Maria (2018) Hyperammonemia and proteostasis in cirrhosis. Curr Opin Clin Nutr Metab Care 21:30-36
Lindenmeyer, Christina C; McCullough, Arthur J (2018) The Natural History of Nonalcoholic Fatty Liver Disease-An Evolving View. Clin Liver Dis 22:11-21
Rausch, John C; Lavine, Joel E; Chalasani, Naga et al. (2018) Genetic Variants Associated With Obesity and Insulin Resistance in Hispanic Boys With Nonalcoholic Fatty Liver Disease. J Pediatr Gastroenterol Nutr 66:789-796
Vuppalanchi, Raj; Siddiqui, Mohammad S; Van Natta, Mark L et al. (2018) Performance characteristics of vibration-controlled transient elastography for evaluation of nonalcoholic fatty liver disease. Hepatology 67:134-144
Hajifathalian, Kaveh; Torabi Sagvand, Babak; McCullough, Arthur J (2018) Effect of Alcohol Consumption on Survival in Nonalcoholic Fatty Liver Disease: A National Prospective Cohort Study. Hepatology :
Brunt, Elizabeth M; Kleiner, David E; Wilson, Laura A et al. (2018) Improvements in Histologic Features and Diagnosis associated with Improvement in Fibrosis in NASH: Results from the NASH Clinical Research Network Treatment Trials. Hepatology :
Harlow, Kathryn E; Africa, Jonathan A; Wells, Alan et al. (2018) Clinically Actionable Hypercholesterolemia and Hypertriglyceridemia in Children with Nonalcoholic Fatty Liver Disease. J Pediatr 198:76-83.e2

Showing the most recent 10 out of 112 publications